HIMS · Hims & Hers Health, Inc.
$29.83
-1.92 (-6.05%)
At close · Aug 26
View the 10-K filed Feb 23, 2026
Customer concentration
— top customer 10% of receivables
One customer — 10% of receivables (As of December 31, 2025)
“As of December 31, 2025, one customer or partner individually represented more than 10% of accounts receivable.”
Market Cap
$7.41B
Shares
233.31M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$29.83
Open$31.04
Day$29.62–31.63
52W close$14.52–62.76
Avg vol 30d14.6M
Short int58.7M · 25.1% float · 4.5d
Short vol61%
Last earningsAug 10, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 9, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+4%
above
Price vs 50-day avg
−7%
below
RSI (14)
48
neutral
MACD trend
Positive
52-week position
32%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+19%
trailing
6-month return
+88%
trailing
YTD return
−8%
this year
Relative strength
+75%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $32 › 200d $29 — 50d above 200d
Institutional flow
Accumulating
+17% holders QoQ · +148 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
25.15% of float · ▼ -5.7% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
520 holders — near 3-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+59%
Y/Y
Gross margin
74%
contracting
EPS growth
−4%
Y/Y
Buyback
$225.0M
remaining
Balance sheet
$228.6M
net cash
Quant / Vol
risk profile
Volatility
93%
annualized · 1-yr
Max drawdown
−77%
past year
ATR
8.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 10, 2026
for the third quarter 2026
Revenue
Initiated
$880M – $900M
prior qtr $753.21M
midpoint +18.2% QoQ
Adjusted EBITDA
Non-GAAP
Initiated
$75M – $95M
Adjusted EBITDA margin
Non-GAAP
Initiated
9% – 11%
for the full year 2026
Revenue
Raised
$3.1B – $3.3B
May 11, 2026
$2.8B – $3B
changed to
Aug 10, 2026
$3.1B – $3.3B
prior FY $2.35B
midpoint +36.3% Y/Y
Adjusted EBITDA
Non-GAAP
Lowered
$275M – $325M
May 11, 2026
$275M – $350M
changed to
Aug 10, 2026
$275M – $325M
Prior guidance
period ended
· from the 8-K filed May 11, 2026
Revenue
· second quarter 2026
$680M – $700M
Adjusted EBITDA
· second quarter 2026
$35M – $55M
Adjusted EBITDA margin
· second quarter 2026
5% – 8%
Guided vs delivered
· last 8 settled
Revenue
second quarter 2026
guided $680M – $700M
$753.21M
Beat +9.2%
Revenue
fourth quarter 2025
guided $605M – $625M
$617.82M
In line
Revenue
full year 2025
guided $2.34B – $2.36B
$2.35B
In line
Revenue
second quarter 2025
guided $530M – $550M
$544.83M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+4%
Bullish
Price vs 50-day avg
−7%
Bearish
RSI (14)
48
Neutral
MACD trend
Positive
Bullish
52-week position
32%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $32 › 200d $29 — 50d above 200d
Institutional flow
Accumulating
+17% holders QoQ · +148 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
25.15% of float · ▼ -5.7% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
520 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $15
Now $30 · 32%
Range high $63
vs 200-day avg +4%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $60.3M | second quarter of 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net (loss) income -86.29M
+47.5M Legal contingencies
+42.12M Stock-based compensation
+29.48M Depreciation and amortization
+28.84M Acquisition and transaction-related costs
+4.63M Restructuring and other related charges
+4.22M Change in fair value of liabilities
+2.02M Payroll tax expense related to stock-based compensation
+1.15M Impairment of long-lived assets
-2.25M Interest income and expense, net
-4.74M Change in fair value of equity securities
-6.34M (Benefit from) provision for income taxes
= Adjusted EBITDA 60.32M
|
|||
| Adjusted EBITDA margin non-GAAP | 8% | Three Months Ended June 30, 2026 | — |
|
|
|||
| Free Cash Flow non-GAAP | -$68.2M | second quarter of 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net cash (used in) provided by operating activities -35.94M
-25.93M Purchases of property, equipment, and intangible assets in investing activities
-6.33M Investment in website development and internal-use software in investing activities
= Free Cash Flow -68.19M
|
|||
| Monthly Revenue per Average Subscriber | $92 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Subscribers (end of period) | 2.89M | Three Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted General and administrative non-GAAP | 59.36M | Three Months Ended March 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP General and administrative 109.67M
-21.94M Stock-based compensation
-15M Legal settlement costs
-13.37M Acquisition and transaction-related costs
= Adjusted General and administrative 59.36M
|
|||
| Adjusted gross margin % non-GAAP | 70% | Three Months Ended March 31, 2026 | — |
| Adjusted Gross Profit non-GAAP | 425.25M | Three Months Ended March 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Gross Profit 396.79M
+28.46M Restructuring and other related charges included within cost of revenue
= Adjusted Gross Profit 425.25M
|
|||
| Adjusted Marketing non-GAAP | 219.19M | Three Months Ended March 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Marketing 222M
-2.82M Stock-based compensation
= Adjusted Marketing 219.19M
|
|||
| Adjusted Net (Loss) Income non-GAAP | -43.6M | Three Months Ended March 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net (loss) income -92.12M
+33.49M Restructuring and other related charges
+15M Legal settlement costs
+13.37M Acquisition and transaction-related costs
-13.34M Tax effects of adjustments
= Adjusted Net (Loss) Income -43.6M
|
|||
| Adjusted Operations and support non-GAAP | 85.36M | Three Months Ended March 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Operations and support 96.5M
-6.11M Stock-based compensation
-5.03M Restructuring and other related charges included within operating expenses
= Adjusted Operations and support 85.36M
|
|||
| Adjusted Technology and development non-GAAP | 40.95M | Three Months Ended March 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Technology and development 46.94M
-5.99M Stock-based compensation
= Adjusted Technology and development 40.95M
|
|||
| Monthly Online Revenue per Average Subscriber | $81 | Year Ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HIMS
this stock
Hims & Hers Health, Inc.
|
$7.41B | -8.1% | +59.0% | — | 25.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.22B | +16.9% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.94B | +2.3% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.77B | +0.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HIMS | -4.1% | +19.3% | +87.9% | +7.4% | -8.1% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | -3.7% | +14.3% | +75.4% | +4.9% | -20.5% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$250.00M
Spent (derived)
$25.00M
Remaining
$225.00M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1773751
CUSIP
433000106
13F (30d)
419 filings
416 filers
Visit website
Investor relations